首页> 美国卫生研究院文献>Annals of the Rheumatic Diseases >Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy.
【2h】

Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy.

机译:关节腔内注射750 kD透明质酸治疗骨关节炎:这是一项针对91位患者的单中心双盲安慰剂对照随机对照试验表明该药缺乏疗效。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

OBJECTIVE--To determine the safety and efficacy of intra-articular injections of hyaluronan in the treatment of osteoarthritis of the knee. METHODS--A randomised double-blind placebo-controlled trial was carried out on 91 patients with radiologically confirmed osteoarthritis of the knee who were recruited from the outpatient clinics. RESULTS--It was found that weekly intraarticular injections of 20 mg of hyaluronan of M(r) = 750,000 (Hyalgan) in 2 ml of buffered saline performed no better than the inert vehicle alone over a five week period. The principal side effects of a transient increase in pain and swelling in the affected knee was observed in 47% of the treatment group compared with 22% of the placebo group. A few patients with radiologically mild disease treated with Hyalgan appeared to experience medium to long-term symptomatic improvement over matched placebo controls as judged by a delayed return to previous NSAID therapy or analgesia other than paracetamol. Patient numbers in the survival groups, however, were too small to be meaningful. CONCLUSION--It is concluded that intraarticular administration of this preparation of 750 kD hyaluronan offers no significant benefit over placebo during a five week treatment period, but incurs a significantly higher morbidity, and therefore has no place in the routine treatment of osteoarthritis.
机译:目的-确定关节内注射透明质酸在膝关节骨性关节炎中的安全性和有效性。方法-对从门诊诊所招募的91例经放射学证实为膝关节骨关节炎的患者进行了一项随机双盲安慰剂对照试验。结果-发现在5周的时间内,每周关节内注射2 mg缓冲盐水中的20 mg透明质酸M(r)= 750,000(Hyalgan)关节腔内注射的效果并不比单独使用惰性载体好。 47%的治疗组观察到患膝疼痛和肿胀短暂增加的主要副作用,而安慰剂组为22%。由Hyalgan治疗的一些放射线较轻的疾病患者似乎比相匹配的安慰剂对照组有中至长期的症状改善,这是通过延迟返回以前的NSAID治疗或对乙酰氨基酚以外的镇痛来判断的。但是,生存组中的患者人数太少而没有意义。结论-结论是,在五周的治疗期内,这种750 kD透明质酸制剂的关节腔内给药对安慰剂没有明显的益处,但是其发病率明显更高,因此在骨关节炎的常规治疗中没有位置。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号